Tigermed roars in its Hong Kong stock trading debut, as Asia’s largest healthcare IPO of 2020 draws traders to its clinical trials

Hangzhou Tigermed Consulting, the biggest listing this year by an Asian health care provider, jumped by as much as 19 per cent in its Hong Kong trading debut, as investors piled into China’s largest clinical researcher, betting that some of its 400 trials under way would bear fruit.Tigermed’s shares began trading at HK$119, soaring from their initial public offering price (IPO) of HK$100. Yuan-denominated A shares of the company, based in the Zhejiang provincial capital, fell by as much as 4.9…

Read the original article at South China Morning Post